{
  "pmcid": "9807536",
  "sha256": "8078e47e4e898314bb45a22a4e827015ac3adc3975797db27419adf48df5976a",
  "timestamp_utc": "2025-11-09T16:22:17.687382+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.50493181818182,
    "reading_ease": 40.1560643939394,
    "word_count": 275
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This phase III trial randomized patients"
      },
      "Participants": {
        "score": 1,
        "evidence": "Patients with Dukes’ B3 and C disease"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized patients to receive continuous infusional 5-FU for 7 days starting within 24 h after curative resection (arm A) or no perioperative 5-FU (arm B)"
      },
      "Objective": {
        "score": 1,
        "evidence": "The primary endpoint of the trial was overall survival in patients with Dukes’ B3 and C disease."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint of the trial was overall survival in patients with Dukes’ B3 and C disease."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From August 1993 to May 2000, 859 patients were enrolled and 855 randomized (arm A: 427; arm B: 428)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "no statistically significant difference in OS [median 10.3 years (95% CI 8.4, 13.2) for perioperative chemotherapy and 9.3 years (95% CI 5.7, 12.3) for no perioperative therapy, one-sided log-rank p = 0.178, HR = 0.88 (95% CI 0.66, 1.16)]"
      },
      "Harms": {
        "score": 1,
        "evidence": "18% of arm A patients experienced grade 3 or greater toxicity."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}